Nuvation Bio to Present Subgroup Data for IBTROZI in Advanced Lung Cancer at WCLC and ESMO
Event summary
- Nuvation Bio will present new subgroup analyses of long-term Phase 2 TRUST-I and TRUST-II data for IBTROZI (taletrectinib) at WCLC (Sept. 15, 2026) and ESMO (Oct. 26, 2026).
- The analyses will examine the efficacy and safety of IBTROZI across key patient subgroups with advanced ROS1-positive NSCLC.
- IBTROZI received FDA approval in June 2025 for locally advanced or metastatic ROS1+ NSCLC.
- TRUST-I (N=173) and TRUST-II (N=189) are pivotal Phase 2 studies evaluating IBTROZI globally.
The big picture
Nuvation Bio's presentation of subgroup data for IBTROZI comes as the company seeks to solidify its position in the competitive ROS1 inhibitor market. The focus on long-term efficacy and safety across diverse patient populations is critical, given the high unmet need in advanced NSCLC with CNS metastases. The upcoming data could influence prescribing patterns and payer negotiations, particularly if it demonstrates consistent benefits in previously treated patients.
What we're watching
- Clinical Efficacy
- How the subgroup analyses will impact IBTROZI's positioning as a standard of care across all lines of advanced ROS1-positive NSCLC.
- Regulatory Strategy
- Whether the data will support potential label expansions or additional approvals in key markets.
- Competitive Dynamics
- The pace at which Nuvation Bio can differentiate IBTROZI from existing ROS1 inhibitors like entrectinib and crizotinib.